Scholar Rock (SRRK) Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 SMA
Go back to Scholar Rock (SRRK) Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 SMA| (NASDAQ: SRRK) | Delayed: 41.49 -0.47 (1.12%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $41.96 | 52 Week High | $ | |||
| Open | $41.58 | 52 Week Low | $ | |||
| Day High | $41.95 | P/E | N/A | |||
| Day Low | $40.76 | EPS | $ | |||
| Volume | 1,207,203 | |||||



